There is one clinical trial.

Clinical Trials

1 CYP19A1 Gene and Pharmacogenetics of Response

Testosterone (T) replacement prevents bone loss and relieves symptoms associated with androgen deficiency in male patients with hypogonadism, but at the expense of an increase in prostate-related adverse events and in the hematocrit values above the normal which may lead to bad circulatory outcomes. Most of the effects of T on the male skeleton are mediated by its conversion to estradiol (E2) by the enzyme aromatase. Genetic variations in the aromatase (CYP19A1) gene result in enzymes with variable activity and variable levels of E2 and T. This project is designed to determine if genetic variations in the CYP19A1 gene will result in differences in the skeletal response and incidence of side effects from T treatment in patients with low T. A large number of male Veterans are on T. Results from this project will help identify patients who would benefit from the therapy from those at risk for side effects, and would definitely have an impact in the future care of these patients and male patients in general once genetic profiling becomes part of the standard of care.

NCT01378299 Hypogonadism Drug: Testosterone Cypionate

MeSH:Hypogonadism

HPO:Gonadotropin deficiency Hypergonadotropic hypogonadism Hypogonadism Hypogonadotropic hypogonadism

Percent Change in Bone Mineral Density (BMD) According to the rs1062033 Polymorphism in the CYP19A1 Gene.

Percent Change in Prostate-specific Antigen (PSA) According to the rs1062033 Polymorphism of the CYP19A1 Gene.

Percent change in bone turnover from baseline to 18 months.. Percent Change in Bone Turnover Markers According to the rs1062033 Polymorphism of the CYP19A1 Gene.

HPO Nodes